Inventiva (NASDAQ:IVA) Sees Large Volume Increase – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-strong trading volume on Wednesday . 1,886,695 shares were traded during trading, an increase of 166% from the previous session’s volume of 709,668 shares.The stock last traded at $3.7750 and had previously closed at $3.86.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IVA shares. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating on shares of Inventiva in a research report on Wednesday. Finally, Guggenheim upped their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.75.

Inventiva Price Performance

The company has a 50-day simple moving average of $4.53 and a two-hundred day simple moving average of $4.86.

Institutional Investors Weigh In On Inventiva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP lifted its holdings in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after buying an additional 43,280 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Inventiva during the fourth quarter valued at approximately $603,000. Seven Fleet Capital Management LP purchased a new position in shares of Inventiva during the first quarter valued at approximately $1,111,000. Eventide Asset Management LLC bought a new position in shares of Inventiva during the fourth quarter valued at approximately $1,155,000. Finally, Simplify Asset Management Inc. purchased a new stake in Inventiva in the fourth quarter worth $1,570,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.